Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) fell 4.1% on Monday . The stock traded as low as $15.23 and last traded at $15.13. 60,225 shares were traded during trading, a decline of 65% from the average session volume of 172,022 shares. The stock had previously closed at $15.77.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.
Get Our Latest Report on Pulse Biosciences
Pulse Biosciences Trading Down 2.8%
The stock's 50-day moving average is $16.99 and its 200 day moving average is $17.91.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock worth $19,958,000 after purchasing an additional 150,506 shares during the period. Bank of America Corp DE boosted its holdings in shares of Pulse Biosciences by 0.4% during the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock worth $13,727,000 after buying an additional 2,884 shares during the period. Geode Capital Management LLC grew its stake in Pulse Biosciences by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock valued at $8,024,000 after buying an additional 3,603 shares during the last quarter. Invesco Ltd. raised its holdings in Pulse Biosciences by 1,956.7% in the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company's stock worth $3,734,000 after acquiring an additional 204,061 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
